JP2001501453A - ヒト腫瘍壊死因子δおよびε - Google Patents
ヒト腫瘍壊死因子δおよびεInfo
- Publication number
- JP2001501453A JP2001501453A JP09532553A JP53255397A JP2001501453A JP 2001501453 A JP2001501453 A JP 2001501453A JP 09532553 A JP09532553 A JP 09532553A JP 53255397 A JP53255397 A JP 53255397A JP 2001501453 A JP2001501453 A JP 2001501453A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- polynucleotide
- tnfδ
- seq
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.以下からなる群から選択されるメンバーに対して少なくとも70%の同一性を 有するポリヌクレオチドを含む、単離されたポリヌクレオチド: (a)配列番号2に示されたアミノ酸配列を含むポリペプチドをコードするポリ ヌクレオチド; (b)配列番号4に示されたアミノ酸配列を含むポリペプチドをコードするポリ ヌクレオチド; (c)配列番号2のアミノ酸39〜アミノ酸233を含むポリペプチドをコードするポ リヌクレオチド; (d)(a)、(b)、または(c)のポリヌクレオチドに相補的であるポリヌクレオチド ;および (e)(a)、(b)、(c)、または(d)のポリヌクレオチドの少なくとも15塩基を含む ポリヌクレオチド。 2.前記ポリヌクレオチドがDNAである、請求項1に記載のポリヌクレオチド。 3.前記ポリヌクレオチドがRNAである、請求項1に記載のポリヌクレオチド。 4.前記ポリヌクレオチドがゲノムDNAである、請求項1に記載のポリヌクレオ チド。 5.配列番号2のアミノ酸を含むポリペプチドをコードする、請求項2に記載の ポリヌクレオチド。 6.配列番号2のアミノ酸39〜アミノ酸233を含むポリペプチドをコードする、 請求項2に記載のポリヌクレオチド。 7.配列番号4のアミノ酸を含むポリペプチドをコードする、請求項2に記載の ポリヌクレオチド。 8.配列番号4のアミノ酸1〜188を含むポリペプチドをコードする、請求項2 に記載のポリヌクレオチド。 9.以下からなる群から選択されるメンバーに対して少なくとも70%同一である ポリヌクレオチドを含む、単離されたポリヌクレオチド: (a)ATCC受託番号第97377号に含まれるヒトcDNAによって発現されるアミノ酸配 列を有する成熟ポリペプチドをコードするポリヌクレオチド; (b)ATCC受託番号第97457号に含まれるヒトcDNAによって発現されるアミノ酸配 列を有する成熟ポリペプチドをコードするポリヌクレオチド; (c)(a)または(b)の該ポリヌクレオチドに相補的であるポリヌクレオチド; (d)(a)、(b)、または(c)の該ポリヌクレオチドの少なくとも15塩基を含むポリ ヌクレオチド。 10.配列番号1のヌクレオチド447〜ヌクレオチド1717を含む、請求項1に記 載のポリヌクレオチド。 11.配列番号1のヌクレオチド332〜ヌクレオチド1717を含む、請求項1に記 載のポリヌクレオチド。 12.配列番号3のヌクレオチド1〜ヌクレオチド564を含む、請求項1に記載 のポリヌクレオチド。 13.請求項2に記載のDNAを含む、ベクター。 14.請求項13に記載のベクターを含む、宿主細胞。 15.請求項14に記載の宿主細胞から前記DNAによりコードされるポリペプチ ドを発現させる工程を包含する、ポリペプチドを産生するためのプロセス。 16.請求項12に記載のベクターを用いて細胞を遺伝子操作する工程を包含し 、それによって該ベクターに含まれるヒトcDNAによってコードされるポリペプチ ドを発現する、細胞を産生するためのプロセス。 17.以下からなる群から選択されるメンバーを含むポリペプチド: (a)配列番号2に示されるアミノ酸配列を有するポリペプチド;および (b)配列番号2に記載のアミノ酸39〜233を含むポリペプチド; (c)配列番号4に記載のアミノ酸1〜188を含むポリペプチド;および (d)(a)、(b)、または(c)に記載のポリペプチドに少なくとも70%の同一性を有 するポリペプチド。 18.前記ポリペプチドが配列番号2のアミノ酸1〜アミノ酸233を含む、請求 項17に記載のポリペプチド。 19.前記ポリペプチドが配列番号2のアミノ酸39〜アミノ酸233を含む、請求 項17に記載のポリペプチド。 20.前記ポリペプチドが配列番号4のアミノ酸1〜アミノ酸188を含む、請求 項17に記載のポリペプチド。 21.請求項17に記載のポリペプチドの活性化を阻害する化合物。 22.TNFδの必要を有する患者の処置のための方法であって、請求項17に記 載のポリペプチドの治療有効量を該患者に投与する工程を包含する、方法。 23.TNFεの必要を有する患者の処置のための方法であって、請求項17に記 載のポリペプチドの治療有効量を該患者に投与する工程を包含する、方法。 24.前記ポリペプチドの前記治療有効量が、該ポリペプチドをコードするDNA を前記患者に提供する工程およびインビボで該ポリペプチドを発現する工程によ って投与される、請求項22に記載の方法。 25.前記ポリペプチドの前記治療有効量が、該ポリペプチドをコードするDNA を前記患者に提供する工程およびインビボで該ポリペプチドを発現する工程によ って投与される、請求項23に記載の方法。 26.TNFδポリペプチドを阻害する必要を有する患者の処置のための方法であ って、請求項21に記載の化合物の治療有効量を該患者に投与する工程を包含す る、方法。 27.TNFεポリペプチドを阻害する必要を有する患者の処置のための方法であ って:請求項21に記載の化合物の治療有効量を該患者に投与する工程を包含す る、方法。 28.請求項17に記載のポリペプチドの過小発現に関連する疾患または疾患に 対する感受性を診断するためのプロセスであって、該ポリペプチドをコードする 核酸配列中の変異を決定する工程を包含する、プロセス。 29.宿主由来のサンプル中の請求項17に記載のポリペプチドの存在を分析す る工程を包含する、診断プロセス。 30.請求項17に記載のポリペプチドに結合し、そしてその活性化を阻害する 化合物を同定するための方法であって、 該ポリペプチドに対するレセプターであって、該レセプターが化合物の該レセ プターへの結合に応答して検出可能なシグナルを提供し得る第2の成分と会合す る、レセプターをその表面に発現する細胞と、分析的に検出可能なTNFδポリペ プチドおよび化合物とを該レセプターに結合し得る条件下で接触させる工程;お よび TNFδと該レセプターとの相互作用から産生されるシグナルの非存在を検出す ることによって、該化合物が該レセプターに結合し、そして阻害するか否かを決 定する工程 を包含する、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2247285A CA2247285C (en) | 1996-03-14 | 1996-03-14 | Human tumor necrosis factor delta and epsilon |
PCT/US1996/003774 WO1997033902A1 (en) | 1996-03-14 | 1996-03-14 | Human tumor necrosis factor delta and epsilon |
CN96180213A CN1214050A (zh) | 1996-03-14 | 1996-03-14 | 人肿瘤坏死因子δ和ε |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003067375A Division JP2003265176A (ja) | 2003-03-12 | 2003-03-12 | ヒト腫瘍壊死因子δおよびε |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001501453A true JP2001501453A (ja) | 2001-02-06 |
Family
ID=27170805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP09532553A Pending JP2001501453A (ja) | 1996-03-14 | 1996-03-14 | ヒト腫瘍壊死因子δおよびε |
Country Status (11)
Country | Link |
---|---|
EP (2) | EP0897390B1 (ja) |
JP (1) | JP2001501453A (ja) |
CN (1) | CN1214050A (ja) |
AT (1) | ATE254135T1 (ja) |
AU (1) | AU726486C (ja) |
CA (1) | CA2247285C (ja) |
DE (1) | DE69630710T2 (ja) |
DK (1) | DK0897390T3 (ja) |
ES (1) | ES2210354T3 (ja) |
PT (1) | PT897390E (ja) |
WO (1) | WO1997033902A1 (ja) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
US6541224B2 (en) | 1996-03-14 | 2003-04-01 | Human Genome Sciences, Inc. | Tumor necrosis factor delta polypeptides |
US7217788B2 (en) | 1996-03-14 | 2007-05-15 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta polypeptides |
DE69730607T2 (de) | 1996-07-19 | 2005-01-27 | Takeda Chemical Industries, Ltd. | Fas ligand ähnliches protein, seine herstellung und verwendung |
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
US6689579B1 (en) | 1996-10-25 | 2004-02-10 | Human Genome Sciences, Inc. | Polynucleotides encoding neutrokine-α |
US6171787B1 (en) | 1997-06-26 | 2001-01-09 | Abbott Laboratories | Member of the TNF family useful for treatment and diagnosis of disease |
WO1999011791A2 (en) * | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
EE200000147A (et) * | 1997-09-12 | 2001-02-15 | Biogen, Incorporated | April - uus kasvuefekte omav valk |
JP2002516069A (ja) * | 1997-09-30 | 2002-06-04 | ファルマシア・アンド・アップジョン・カンパニー | Tnf関連死リガンド |
US6297022B1 (en) | 1997-10-08 | 2001-10-02 | Smithkline Beecham Corporation | Method of identifying agonists and antagonists for tumor necrosis related receptor TR1 |
CA2310987A1 (en) * | 1997-11-26 | 1999-06-03 | Eli Lilly And Company | Tnf ligand family gene |
WO1999026976A1 (en) * | 1997-11-26 | 1999-06-03 | Eli Lilly And Company | Tnf ligand family gene |
US6297367B1 (en) | 1997-12-30 | 2001-10-02 | Chiron Corporation | Polynucleotide encoding TNFL1 |
WO1999033980A2 (en) * | 1997-12-30 | 1999-07-08 | Chiron Corporation | Members of tnf and tnfr families |
US6365369B1 (en) * | 1998-04-01 | 2002-04-02 | Human Genome Sciences, Inc. | Prostate specific secreted protein |
WO2001060397A1 (en) | 2000-02-16 | 2001-08-23 | Genentech, Inc. | Uses of agonists and antagonists to modulate activity of tnf-related molecules |
ES2151403B1 (es) * | 1998-07-13 | 2001-07-01 | Hernandez Bronchud Miguel | Linea celular transformada de rata productora de tnf-alfa humano recombinante. |
AU1467000A (en) * | 1998-11-04 | 2000-05-22 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A novel tumor necrosis factor family member, drl, and related compositions and methods |
US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
BR0007719A (pt) | 1999-01-25 | 2001-11-13 | Biogen Inc | Baff, agentes de bloqueio relacionados e uso dosmesmos no estìmulo e na inibição de células b e deimunoglobulinas em respostas imunológicas |
US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
HU230583B1 (hu) | 1999-08-17 | 2017-02-28 | Biogen Idec Ma Inc. | BAFF-receptor (BCMA) alkalmazásai immunszabályozó szerként |
UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
AU3495301A (en) | 2000-02-11 | 2001-08-20 | Biogen Inc | Heterologous polypeptide of the tnf family |
AU2001282856A1 (en) * | 2000-06-15 | 2001-12-24 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
US7220840B2 (en) | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
AU6842701A (en) | 2000-06-16 | 2002-01-14 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
AU2001288301A1 (en) | 2000-08-18 | 2002-03-04 | Human Genome Sciences, Inc. | Binding polypeptides and methods based thereon |
UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
US7189820B2 (en) | 2001-05-24 | 2007-03-13 | Human Genome Sciences, Inc. | Antibodies against tumor necrosis factor delta (APRIL) |
JP2004535182A (ja) | 2001-05-24 | 2004-11-25 | ザイモジェネティクス,インコーポレイティド | Taci−免疫グロブリン融合タンパク質 |
JP5524441B2 (ja) | 2003-03-28 | 2014-06-18 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 短縮されたbaffレセプター |
EP1709072A1 (en) * | 2004-01-29 | 2006-10-11 | Genentech, Inc. | Variants of the extracellular domain of bcma and uses thereof |
US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
EP1922079A2 (en) | 2005-08-09 | 2008-05-21 | ZymoGenetics, Inc. | Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules |
KR20080056714A (ko) | 2005-08-09 | 2008-06-23 | 지모제넥틱스, 인코포레이티드 | TACI―Ig 융합 분자를 사용하여 B―세포 악성종양을치료하는 방법 |
WO2007142667A2 (en) | 2005-10-13 | 2007-12-13 | Human Genome Sciences, Inc. | Treatment of patients with autoantibody positive disease |
US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
AU2006318539B2 (en) | 2005-11-23 | 2012-09-13 | Genentech, Inc. | Methods and compositions related to B cell assays |
US8211649B2 (en) | 2006-03-31 | 2012-07-03 | Human Genome Sciences, Inc. | Methods of diagnosing and prognosing hodgkin's lymphoma |
AU2007249223B2 (en) | 2006-05-15 | 2012-08-02 | Ares Trading S.A. | Methods for treating autoimmune diseases using a TACI-Ig fusion molecule |
WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0313104A3 (en) * | 1984-12-21 | 1989-07-12 | Biogen, Inc. | Purification, production and use of tumor necrosis factors |
-
1996
- 1996-03-14 CN CN96180213A patent/CN1214050A/zh active Pending
- 1996-03-14 PT PT96910483T patent/PT897390E/pt unknown
- 1996-03-14 EP EP96910483A patent/EP0897390B1/en not_active Expired - Lifetime
- 1996-03-14 AT AT96910483T patent/ATE254135T1/de active
- 1996-03-14 DK DK96910483T patent/DK0897390T3/da active
- 1996-03-14 DE DE69630710T patent/DE69630710T2/de not_active Expired - Lifetime
- 1996-03-14 EP EP03012254A patent/EP1362916A3/en not_active Withdrawn
- 1996-03-14 ES ES96910483T patent/ES2210354T3/es not_active Expired - Lifetime
- 1996-03-14 WO PCT/US1996/003774 patent/WO1997033902A1/en active IP Right Grant
- 1996-03-14 JP JP09532553A patent/JP2001501453A/ja active Pending
- 1996-03-14 AU AU53665/96A patent/AU726486C/en not_active Ceased
- 1996-03-14 CA CA2247285A patent/CA2247285C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE254135T1 (de) | 2003-11-15 |
EP0897390A1 (en) | 1999-02-24 |
ES2210354T3 (es) | 2004-07-01 |
AU5366596A (en) | 1997-10-01 |
EP1362916A2 (en) | 2003-11-19 |
AU726486C (en) | 2004-02-05 |
DE69630710T2 (de) | 2004-09-23 |
WO1997033902A1 (en) | 1997-09-18 |
CA2247285A1 (en) | 1997-09-18 |
EP0897390B1 (en) | 2003-11-12 |
DK0897390T3 (da) | 2004-03-08 |
CN1214050A (zh) | 1999-04-14 |
EP0897390A4 (ja) | 1999-04-07 |
PT897390E (pt) | 2004-03-31 |
AU726486B2 (en) | 2000-11-09 |
CA2247285C (en) | 2011-11-08 |
DE69630710D1 (de) | 2003-12-18 |
EP1362916A3 (en) | 2004-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001501453A (ja) | ヒト腫瘍壊死因子δおよびε | |
US5874240A (en) | Human 4-1BB receptor splicing variant | |
EP2017337A1 (en) | Human tumor necrosis factor receptors | |
WO1997033899A1 (en) | Apoptosis inducing molecule i | |
EP1025228A1 (en) | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 | |
US7094564B1 (en) | Human tumor necrosis factor receptor | |
CA2211003A1 (en) | Human tumor necrosis factor receptor | |
KR20000064765A (ko) | 케모카인 알파 2 | |
US7049422B2 (en) | Tumor necrosis related receptor, TR7 | |
US6509170B1 (en) | Polynucleotides encoding human tumor necrosis factor delta | |
US20030166097A1 (en) | Human tumor necrosis factor receptor | |
JP2001509663A (ja) | ヒト腫瘍壊死因子レセプター様遺伝子 | |
JPH11507237A (ja) | 単球走化性蛋白質−4 | |
US20060171918A1 (en) | Apoptosis inducing molecule I | |
US6130061A (en) | Human stem cell antigen 2 | |
KR100490707B1 (ko) | 사람의종양괴사인자델타및엡실론 | |
AU2003236393B2 (en) | Methods of Treating or Preventing Inflammation or Rheumatoid Arthritis | |
AU761216B2 (en) | Human tumor necrosis factor delta and epsilon | |
JP2008194038A (ja) | ヒト腫瘍壊死因子δおよびε | |
AU716415B2 (en) | Pineal gland specific gene-1 | |
JP2003265176A (ja) | ヒト腫瘍壊死因子δおよびε | |
JP2003024089A (ja) | ヒト腫瘍壊死因子受容体 | |
CA2215383A1 (en) | Human tumor necrosis factor receptor | |
JPH11503007A (ja) | ヒト腫瘍壊死因子受容体 | |
JP2000506366A (ja) | ケモカインアルファ3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050830 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051108 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060224 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080122 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080411 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080526 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080521 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080630 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080617 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080728 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080715 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081007 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090203 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090305 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20090402 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101209 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101214 |